Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity

The BRAF inhibitor vemurafenib, approved for treating patients with BRAF V600E-mutant and unresectable or metastatic melanomas, rapidly induces cutaneous adverse events, including hyperkeratotic skin lesions and cutaneous squamous cell carcinomas (cSCC). To determine, how vemurafenib would provoke t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tham, Marius, Stark, Hans-Jürgen, Jauch, Anna, Harwood, Catherine, Pavez Lorie, Elizabeth, Boukamp, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842679/
https://www.ncbi.nlm.nih.gov/pubmed/35174094
http://dx.doi.org/10.3389/fonc.2022.827985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842679/
https://www.ncbi.nlm.nih.gov/pubmed/35174094
http://dx.doi.org/10.3389/fonc.2022.827985

Ejemplares similares